175 Innovation Boulevard
Wilmington, DE 19805
United States
302 467 1280
https://preludetx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 128
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, CEO & Director | 905.92k | N/A | 1966 |
Dr. Edna Huang M.D. | President & Chief Medical Officer | 865.63k | N/A | 1973 |
Lindsey Trickett | Vice President of Investor Relations | N/A | N/A | N/A |
Ms. Michele Porreca M.B.A. | Chief People Officer | N/A | N/A | N/A |
Dr. Andrew P. Combs Ph.D. | Executive VP & Chief Chemistry Officer | 562.46k | N/A | 1967 |
Mr. Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine | N/A | N/A | N/A |
Dr. William B. Novotny M.D. | Senior Vice President of Clinical Development | N/A | N/A | N/A |
Dr. Wan-Jen Hong M.D. | Senior Vice President of Clinical Development | N/A | N/A | 1979 |
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Incorporated’s ISS Governance QualityScore as of April 29, 2024 is 9. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 10; Compensation: 9.